BRIEF—Shionogi launches Mulpleta in the USA

Japan’s Shionogi has announced the US launch of Mulpleta (lusutrombopag), a once-daily, oral thrombopoietin (TPO) receptor blocker, following US Food and Drug Administration approval on July 31, 2018.

The therapy was approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.

Chief executive Takayuki Yoshioka said, “As adult patients with CLD often undergo procedures that could put them at increased risk for bleeding, this treatment will offer physicians and patients an option other than platelet transfusions.”

The firm has also launched a support center for physicians and patients to promote market access and adoption.